Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation

Jonathan H. Hsu, Benoit H. Mulsant, Eric J. Lenze, Jordan F. Karp, Helen Lavretsky, Steven P. Roose, Charles F. Reynolds, Daniel M. Blumberger

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Objective Treatment history can inform clinical decisions about subsequent treatment choices. The authors examined the impact of prior antidepressant treatment on treatment outcomes with venlafaxine only and then with augmentation with aripiprazole or placebo in depressed older adults. Methods The authors analyzed outcome data from a randomized, placebo-controlled clinical trial of aripiprazole augmentation in depressed older adults. The study consisted of an open-label lead-in phase with venlafaxine XR, followed by a placebo-controlled phase of aripiprazole augmentation. Treatment history was assessed with the Antidepressant Treatment History Form. Results Documented prior treatment failure predicted a reduced remission rate with venlafaxine. However, aripiprazole augmentation was efficacious in those with prior treatment failure (42.6% remission with aripiprazole versus 25.8% with placebo; χ2 = 3.87 df = 1, p = 0.049). Conclusion Aripiprazole augmentation is an efficacious strategy in older depressed adults who fail to remit with two or more adequate antidepressant trials, including a course of venlafaxine.

Original languageEnglish (US)
Pages (from-to)918-922
Number of pages5
JournalAmerican Journal of Geriatric Psychiatry
Issue number10
StatePublished - Oct 1 2016
Externally publishedYes


  • Geriatric depression
  • antidepressant
  • aripiprazole
  • augmentation
  • randomized controlled trial
  • treatment resistance
  • venlafaxine

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this